Related Experiment Video
Updated: Nov 1, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
2.1K
Pharmacotherapy Considerations in Heart Failure with Mildly-Reduced Ejection Fraction.
Carrie Baker1,2, Scott L Perkins2, Erika Schoenborn2,3
122357Cape Fear Valley Medical Center, Fayetteville, NC, USA.
Journal of Pharmacy Practice
|June 24, 2021
Summary
Heart failure with mildly reduced ejection fraction (HFmrEF) lacks clear treatment guidelines. This review explores HFmrEF epidemiology, pathophysiology, and therapies to optimize patient care and prevent disease progression.
Area of Science:
- Cardiology
- Heart Failure Research
- Pharmacology
Background:
- Heart failure with mildly reduced ejection fraction (HFmrEF) is a recently defined clinical entity.
- HFmrEF patients represent approximately 25% of all heart failure cases.
- Current treatment strategies for HFmrEF remain largely undefined, lacking authoritative guidance.
Purpose of the Study:
- To provide a comprehensive resource for clinicians managing HFmrEF.
- To discuss the epidemiology and pathophysiology of HFmrEF.
- To review current and emerging pharmacotherapies for HFmrEF management.
Main Methods:
- Literature review of HFmrEF definitions, epidemiology, and pathophysiology.
- Analysis of recent publications on HFmrEF treatment strategies.
- Review of pharmacologic agents and their clinical application in HFmrEF.
Main Results:
- HFmrEF is defined as left ventricular ejection fraction between 41%-49%.
- Evidence suggests that therapies for reduced ejection fraction may benefit HFmrEF patients.
- Optimal medical management for HFmrEF is crucial for preventing disease progression.
Conclusions:
- HFmrEF requires further investigation to determine if it is a distinct phenotype or transitional state.
- Appropriate management of HFmrEF offers clear cardiovascular benefits.
- Optimizing pharmacotherapeutic approaches is essential for improving outcomes in HFmrEF patients.
Related Concept Videos
01:30Heart Failure V: Medical Management
60
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
60
01:22Heart Failure VI: Adjunct Therapies
68
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
68
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
632
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
632
01:22Heart Failure Drugs: β-Blockers
538
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
01:30Heart Failure IV: Classification and Diagnostic Evaluation
93
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
93
01:30Heart Failure VII: Nursing Interventions
207
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
207